Disclosures for "Early engagement with the Alzheimer’s disease (AD) community to gain insights into designing the SKYLINE trial in cognitively unimpaired people at risk for progression due to AD")
-
Mrs. Rose has received personal compensation for serving as an employee of Roche. Mrs. Rose has stock in Roche .
-
Ms. Lynn has nothing to disclose.
-
Dr. Langbaum has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alector. Dr. Langbaum has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Denovo Biopharma. Dr. Langbaum has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. The institution of Dr. Langbaum has received research support from Eli Lilly.
-
Ms. Langlois has received personal compensation for serving as an employee of Banner Alzheimer's Institute.
-
Emma Dodd has received personal compensation for serving as an employee of Roche Pharmaceuticals. Emma Dodd has stock in Roche Pharmaceuticals.
-
Ms. Roeser has nothing to disclose.
-
Gesine Respondek, MD has received personal compensation for serving as an employee of Hoffmann-La Roche. Gesine Respondek, MD has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Gesine Respondek, MD has stock in Hoffmann-La Roche.
-
Dr. Ostrowitzki has received personal compensation for serving as an employee of F. Hoffmann-La Roche Ltd. Dr. Ostrowitzki has stock in F. Hoffmann-La Roche Ltd.